Sino Biological Introduces 4RISE for AI-Designed Molecule Validation

From computational predictions to laboratory evidence

AI systems can rapidly generate protein candidates, but Sino Biological says experimental validation is still needed to assess whether those candidates express successfully, bind their targets and show useful biological properties. The company, a recombinant protein technology provider listed on the Shenzhen Stock Exchange as 301047.SZ, positions 4RISE™ as a way to connect computational molecule design with laboratory results.

The name reflects four capabilities: Rapid, In-Depth, Seamless and Empirical. Together, they cover expression, target access, binding analysis, developability testing and functional validation. This is intended to help researchers evaluate candidates and use experimental results to guide later design decisions.

Rapid expression and high-throughput binding analysis

Under the Rapid component, Sino Biological says its XPressMAX™ cell-free protein synthesis system can express proteins in approximately 3 hours, with success rates exceeding 99% in established workflows. The service is paired with more than 11,000 ready-to-use target proteins and high-throughput surface plasmon resonance and biolayer interferometry analysis.

According to the company, applicable workflows can produce AI-ready binding data in as little as 3 days. Structure data and API access are also available for downstream retrieval, analysis and optimization. Sino Biological says faster expression, screening and data delivery can help researchers identify promising candidates and continue AI-driven design cycles more quickly.

Testing beyond target binding

4RISE™ is designed to assess more than binding and kinetic characteristics. Sino Biological says the platform includes more than 20 developability assays, as well as molecular and cell-based functional assays. These tests are intended to help researchers examine candidate quality, biological activity and suitability for further development.

The service combines cell-free and mammalian expression platforms to support different molecule types and expression requirements. Its integrated offering covers sequence screening, antibody production, binding characterization, developability assessment and functional validation, alongside the company’s in-house target protein portfolio.

Experience with AI-designed molecules

Sino Biological says it has supported AI-designed molecules including miniproteins, VHH, scFv, Fab, IgG, enzymes and cytokines. The company also reports collaborations with more than 50 AI companies, which it describes as providing hands-on experience in wet-lab validation.

“AI-driven discovery requires more than computational predictions. Researchers need reliable experimental evidence to evaluate candidates and guide subsequent design decisions,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. He said 4RISE™ combines rapid expression, target resources and in-depth validation to help researchers move faster and gain deeper insights. For users developing AI-designed proteins, the announcement presents 4RISE™ as an integrated route from sequence screening to candidate evaluation, rather than a binding test alone.